Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON43309
NL-OMON43309
Recruiting
Not Applicable

Co-stimulatory and -inhibitory molecules on tumor-infiltrating lymphocytes from cholangiocarcinoma - Co-stimulatory and -inhibitory molecules in CCA

Stichting Leveronderzoek0 sites102 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbile duct cancercholangiocarcinoma10019815

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
bile duct cancer
Sponsor
Stichting Leveronderzoek
Enrollment
102
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Stichting Leveronderzoek

Eligibility Criteria

Inclusion Criteria

  • •Adult cholangiocarcinoma (CCA) patients that will undergo surgery for this disease.

Exclusion Criteria

  • •Patients who refuse blood donation/participation in the study
  • •Patients with a severe immunocompromised condition, or patients taking immunosuppressive medication

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Costimulatory and co-inhibitory molecules on tumor-infiltrating lymphocytes from hepatocellular carcinoma and cholangiocarcinoma
NL-OMON53120Erasmus MC, Universitair Medisch Centrum Rotterdam272
Recruiting
Not Applicable
Costimulatory and -inhibitory molecules on tumor-infiltrating lymphocytes from colorectal carcinoma and its metastasesbowel cancercolorectal carcinoma10017991
NL-OMON43140Stichting Leveronderzoek677
Completed
Not Applicable
Investigation of correlation between antitumor effect of combined lapatinib/capecitabine therapy and p95HER2, PTEN and PIK3CA in patients with HER2 positive breast cancer
JPRN-UMIN000007153Kyushu Breast Cancer Study Group200
Active, not recruiting
Phase 1
A study of the use of apalutamide (ARN509) to reduce tumour volumes in men on active surveillance for prostate cancer
EUCTR2017-001700-29-GBCambridge University Hospitals NHS Foundation Trust & The University of Cambridge10
Completed
Phase 2
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast CancerBreast Cancer
NCT00881361Alliance for Clinical Trials in Oncology756